UNSPSC 51312600: Antihistamine or H1 blocker imidazoles

Antihistamine or H1 blocker drugs made from compounds with a benzene fused to imidazoles.

UNSPSC 51312600 Antihistamine or H1 blocker imidazoles is a Class code that nominally encompasses specific pharmaceutical agents, but recent state and local procurement activity shows the code tagged to a broader pharmaceutical and health-supply acquisition practice — including naloxone (an opioid antagonist, not an antihistamine), drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products procured through state health agencies and cooperative purchasing alliances. State and local buyers under this code include county health departments, state human services and health commissions, and multi-state cooperative purchasing organizations. The actual work consists of bulk pharmaceutical procurement with quarterly or annual delivery cycles, compliance with manufacturing and supply-chain security standards (cGMP, DSCSA, FDA requirements), mandatory use of authorized pharmaceutical wholesalers, and electronic ordering through procurement portals or eProcurement systems.

Recent activity spans Florida, Texas, and Minnesota through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with contract effectiveness July 1, 2026. The code shows material mismatch with its nominal scope — antihistamine procurement is not the primary activity — and bidders should verify specific product eligibility against recent solicitations rather than relying on the code name alone.